1、WelcomeContentClick below to navigate through the documentGiovannis first impressionsTop 10 questions from shareholdersSave the dateAppendixExternal recognition of our sustainability progressOur continued commitment to malaria and NTDsEdition no.22 Q2 2025 Impact and Sustainability Update to investo

2、rs For any questions and comments,please reach out to:Sloan SimpsonGlobal Head of Investor R+1 862 345 4440Maria Victoria CuevasInvestor Relations Executive Director&ESG H+41 79 586 52 85Dear investors and analysts,In our Q2 update,we share first impressions from Giovanni Caforio,the new Chairman of

3、 the Novartis Board of Directors.We also highlight our ongoing commitment to addressing neglected tropical diseases,and malaria,with a major milestone this quarter:the first approval for Coartem Baby.In addition,we report on recognition for our progress towards achieving our climate goals,and invite

4、 you to join our 12th annual social impact and sustainability event.As always,we include top questions from shareholders during Q2 and our responses.We thank you for your continued engagement.Q2 impact and sustainability update|2ContentClick below to navigate through the documentWelcomeGiovannis fir

5、st impressionsTop 10 questions from shareholdersSave the dateAppendixExternal recognition of our sustainability progressOur continued commitment to malaria and NTDsGiovannis first impressions1.What attracted you to the role of Chairman at Novartis?Ive long admired Novartis for its deep commitment to

6、 science and innovation.The opportunity to contribute to a company with a focus on breakthrough research and a strong pipeline of transformative therapies was especially compelling.I was also drawn to the Novartis global reach serving patients in over 100 countries,with 2024 net sales distributed ac